Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination

Accepted for Publication: November 29, 2021.

Published Online: January 24, 2022. doi:10.1001/jamaneurol.2021.5109

Corresponding Author: Marton König, MD, PhD, Department of Neurology, Oslo University Hospital, PO Box 4956, Nydalen, N-0424 Oslo, Norway (makoni@ous-hf.no).

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 König M et al. JAMA Neurology.

Author Contributions: Dr König had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Lund-Johansen and Nygaard are co–last authors.

Concept and design: König, Vaage, Lund-Johansen, Nygaard.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: König, Lund-Johansen.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: König, Tran, Nygaard.

Obtained funding: Nygaard.

Administrative, technical, or material support: König, Tran, Holmøy, Vaage, Nygaard.

Supervision: Nygaard.

Conflict of Interest Disclosures: Dr König reported receiving speaker honoraria from Novartis, Biogen, and AstraZeneca outside the submitted work. Dr Holmøy reported receiving speaker honoraria from Merck, Biogen, Genzyme, Sanofi, Novartis, Roche, and Bristol Myers Squibb during the conduct of the study. No other disclosures were reported.

Funding/Support: This study was funded by the Coalition for Epidemic Preparedness Innovations and Oslo University Hospital.

Role of the Funder/Sponsor: The Coalition for Epidemic Preparedness Innovations and Oslo University Hospital had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank Mathias Herstad Øverås, MD, Oslo University Hospital, Oslo, Norway; Adity Chopra, MD, PhD, Oslo University Hospital; Åslaug Rudjord Lorentzen, MD, PhD, Sørlandet Hospital; Siri Mjaaland, MD, PhD, Norwegian Institute of Public Health, Division of Infection Control, Oslo, Norway; Ingeborg Sundsvalen Aaberge, MD, PhD, Norwegian Institute of Public Health, Division of Infection Control; Kjell-Morten Myhr, MD, PhD, Haukeland University, Bergen, Norway; Stig Wergeland, MD, PhD, Haukeland University; Tone Berge, MD, PhD, Metropolitan University, Oslo, Norway; Hanne Flinstad Harbo, MD, PhD, Oslo University Hospital; Øivind Fredvik Torkildsen, MD, PhD, Haukeland University Hospital; Elisabeth Gulowsen Celius, MD, PhD, Oslo University Hospital; Ludvig Andre Munthe, MD, PhD, Oslo University Hospital; Randi Karlsen, MSc, Oslo University Hospital; Lars Skattebøl, MD, Oslo University Hospital; Einar August Høgestøl, MD, PhD, Oslo University Hospital; Rebecca Cox, MD, PhD, University of Bergen, Bergen, Norway; the Bergen COVID-19 Research Group, and the Coalition for Epidemic Preparedness Innovations for their cooperation and support. No one received financial compensation for their contribution.